Shuhei Nakanishi

Shuhei Nakanishi

Auto-generated profile, based on publicly available information

Shuhei Nakanishi

Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
TKTomoe Kinoshita
Tomoe Kinoshita
MSMasashi Shimoda
Masashi Shimoda
KNKoji Nakashima
Koji Nakashima
YFYoshiro Fushimi
Yoshiro Fushimi
YHYurie Hirata
Yurie Hirata
HKHideaki Kaneto
Hideaki Kaneto
Aims/Introduction: Non‐alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it is known that the presence of type 2 diabetes mellitus leads to the aggravation of NAFLD. The aim of this study was to compare the possible effects of three kinds of oral hypoglycemic agents on NAFLD in individuals with type 2 diabetes mellitus.Materials and Methods: We carried out a prospective clinical trial (a randomized and open‐label study) in patients with type 2 diabetes mellitus and NAFLD. A total of 98 patients were randomly allocated either to the dapagliflozin (n = 32), pioglitazone (n = 33) or glimepiride (n = 33) group, and the patients took these drugs for 28 weeks. The primary end‐point was the change of the liver‐to‐spleen ratio on abdominal computed tomography.Results: There was no difference in baseline clinical characteristics among the three groups. Dapagliflozin, pioglitazone and glimepiride ameliorated hyperglycemia similarly. Bodyweight and visceral fat area were significantly decreased only in the dapagliflozin group. Serum adiponectin levels were markedly increased in the pioglitazone group compared with the other two groups. Dapagliflozin and pioglitazone, but not glimepiride, significantly increased the liver‐to‐spleen ratio, and the effects of dapagliflozin and pioglitazone on the liver‐to‐spleen ratio were comparable.Conclusions: The present study showed that the decrease of visceral fat area and the increase of adiponectin level contributed to the improvement of NAFLD in patients with type 2 diabetes mellitus. Furthermore, dapagliflozin and pioglitazone exerted equivalent beneficial effects on NAFLD in patients with type 2 diabetes mellitus, although it seemed that these two drugs had different mechanisms of action.

Verified
Journal Article
Open access
PDF file
HKHideaki Kaneto
Hideaki Kaneto
TKTomohiko Kimura
Tomohiko Kimura
MSMasashi Shimoda
Masashi Shimoda
AOATSUSHI OBATA
ATSUSHI OBATA
JSJunpei Sanada
Junpei Sanada
KKKohei Kaku
Kohei Kaku
Fundamental pancreatic β-cell function is to produce and secrete insulin in response to blood glucose levels. However, when β-cells are chronically exposed to hyperglycemia in type 2 diabetes mellitus (T2DM), insulin biosynthesis and secretion are decreased together with reduced expression of insulin transcription factors. Glucagon-like peptide-1 (GLP-1) plays a crucial role in pancreatic β-cells; GLP-1 binds to the GLP-1 receptor (GLP-1R) in the β-cell membrane and thereby enhances insulin secretion, suppresses apoptotic cell death and increase proliferation of β-cells. However, GLP-1R expression in β-cells is reduced under diabetic conditions and thus the GLP-1R activator (GLP-1RA) shows more favorable effects on β-cells at an early stage of T2DM compared to an advanced stage. On the other hand, it has been drawing much attention to the idea that GLP-1 signaling is important in arterial cells; GLP-1 increases nitric oxide, which leads to facilitation of vascular relaxation and suppression of arteriosclerosis. However, GLP-1R expression in arterial cells is also reduced under diabetic conditions and thus GLP-1RA shows more protective effects on arteriosclerosis at an early stage of T2DM. Furthermore, it has been reported recently that administration of GLP-1RA leads to the reduction of cardiovascular events in various large-scale clinical trials. Therefore, we think that it would be better to start GLP-1RA at an early stage of T2DM for the prevention of arteriosclerosis and protection of β-cells against glucose toxicity in routine medical care.

23 September 2010 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
NSNakanishi Shuhei
Nakanishi Shuhei
SSSanni Söderlund
Sanni Söderlund
MJMatti Jauhiainen
Matti Jauhiainen
MTMarja-Riitta Taskinen
Marja-Riitta Taskinen
Objectives: To study the resistance of HDL particles to direct oxidation in respect to the distribution of HDL particles. Design and Methods: We studied HDL composition, subclass distribution, and the kinetics of CuSO4-induced oxidation of total HDL and HDL3 in vitro in 36 low-HDL-C subjects and in 41 control subjects with normal HDL-C. Results: The resistance of HDL3 to oxidation, as assessed from the propagation rate was significantly higher than that of total HDL. The propagation rate and diene formation during HDL oxidation in vitro was attenuated in HDL derived from low-HDL-C subjects. Propagation rate and maximal diene formation during total HDL oxidation correlated significantly with HDL mean particle size. The propagation rate of total HDL oxidation in vitro displayed a significant positive association with HDL2 particle mass and HDL mean particle size by multiple regression analyses. Conclusions: These observations highlight that the distribution of HDL subpopulations has important implications for the potential of HDL as an anti-oxidant source.

1 September 2008 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
SNS. Nakanishi
S. Nakanishi
KYK. Yamane
K. Yamane
WOW. Ohishi
W. Ohishi
RNR. Nakashima
R. Nakashima
MYM. Yoneda
M. Yoneda
NKN. Kohno
N. Kohno

19 July 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
SNShuhei Nakanishi
Shuhei Nakanishi
MIMasahiro Iwamoto
Masahiro Iwamoto
HSHisanori Shinohara
Hisanori Shinohara
HIHideyuki Iwamoto
Hideyuki Iwamoto
HKHideaki Kaneto
Hideaki Kaneto
Aims/Introduction: This study examined the association between body mass index (BMI) and the risk of sarcopenia in Japanese type 2 diabetes patients.Materials and Methods: Patients with type 2 diabetes who visited an outpatient clinic comprised the study’s participants. Sarcopenia was defined using the definition of the Asian Working Group for Sarcopenia 2014. The area under the curve was examined for the presence of sarcopenia based on the receiver operating characteristic curve of BMI.Results: Among 1,137 patients, 210 were diagnosed with low grip strength, 78 with slow gait speed, 444 with low muscle mass and 142 with sarcopenia. The optimal cut‐off point of BMI level for risk of sarcopenia was 24.4 kg/m2 (area under the curve 0.729, 95% confidence interval 0.688–0.770, sensitivity 0.587, specificity 0.789). Furthermore, the receiver operating characteristic curve of BMI for sarcopenia did not significantly differ (P = 0.09) from that of gait speed, an established marker of sarcopenia. In both the male and female groups, there was no difference between the receiver operating characteristic curves of BMI and gait speed for sarcopenia. (P = 0.23 and P = 0.40, respectively).Conclusions: These results suggest that a BMI <24 kg/m2 among Japanese patients with type 2 diabetes could increase their risk of sarcopenia, the extent of which is equivalent to the risk for sarcopenia from slow gait speed in this study. Further prospective investigation, however, is required.

1 September 2019 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
SNShuhei Nakanishi
Shuhei Nakanishi
HHHidenori Hirukawa
Hidenori Hirukawa
MSMasashi Shimoda
Masashi Shimoda
FTFuminori Tatsumi
Fuminori Tatsumi
KKKenji Kohara
Kenji Kohara
HKHideaki Kaneto
Hideaki Kaneto
This study examined the association among the onset of diabetic kidney disease (DKD), blood glucose levels (HbA1C), and body mass index (BMI) in Japanese patients with type 2 diabetes mellitus. Patients eligible for this study included those with type 2 diabetes who visited the outpatient clinic at Kawasaki Medical School Hospital between 2000 and 2018 and were followed up for more than two years. The Cox proportional hazards model was used in four categories of subjects: at the beginning of the follow-up period, "controlled" or "uncontrolled" glycemic control based on HbA1c and "overweight" or "non-overweight" based on BMI. After dividing the participants into four categories according to HbA1c (lower than 7.0% (C) or higher (U)), and BMI (25 kg/m2 or higher (O) or lower (N)), hazard ratios for groups CO, UN, and UO were 1.40 (95% CI 1.03-1.90, P = 0.030), 1.40 (1.04-1.88, P = 0.027), and 1.54 (1.12-2.11, P = 0.008), respectively, compared with the CN reference group, after adjustment was made for age, sex, duration of diabetes, and medication for hypertension or dyslipidemia. Maintenance of both an HbA1c level lower than 7.0% and a BMI lower than 25 kg/m2 was important for the prevention of DKD in Japanese patients with type 2 diabetes mellitus. Both factors had a similar effect on DKD in this study.